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Introduction: Ameloblastoma is a benign odontogenic neoplasm of the jaw, rarely presenting as a malignant
tumor. Although it is very important to discriminate ameloblastoma from ameloblastic carcinoma in order to decide
the appropriate operative procedure, this is difficult using conventional CT and MRI.
Case descriptions: We report a case of maxillar ameloblastoma in a 78-year-old man where FDG-PET/CT was useful
for making this discrimination. CT demonstrated a 31 × 43 × 46-mm mass in the left posterior maxillary sinus with
destruction of its posterior and lateral wall and alveolar bone. MRI demonstrated a hypo- to isointense
heterogeneous pattern on T1WI, heterogeneous hyperintensity with a prominent high-signal spot on T2WI, high
signal intensity on DWI reflecting restricted diffusion, and strong heterogeneous enhancement. Because FDG-PET/
CT showed mild FDG uptake (SUVmax 2.40) by the mass, ameloblastoma, rather than ameloblastic carcinoma, was
considered to be the correct diagnosis.
Discussion and evaluation: It appears that ameloblastic carcinoma shows intense FDG uptake, whereas
ameloblastoma shows mild or moderate FDG uptake, and only rarely intense FDG uptake. Our experience suggests
that FDG-PET/CT may be effective for discriminating ameloblastoma from ameloblastic carcinoma. Especially, in
cases showing mild FDG uptake, benign ameloblastoma would seem the most likely diagnosis.
Conclusions: FDG-PET/CT may be useful as an adjunctive modality for diagnosis, treatment planning and
surveillance of ameloblastoma and ameloblastic carcinoma.
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Ameloblastoma is a benign odontogenic neoplasm de-
rived from ameloblastic epithelial tissue. It comprises
only 1% of all jaw tumors and 11% of all odontogenic
neoplasms (being the second most common) (Neville
et al. 2002). The 2005 WHO histological classification of
odontogenic tumors classified ameloblastoma into several
types: solid/multicystic, extraosseous/peripheral, desmo-
plastic, and unicystic (Gardner et al. 2005). Although ame-
loblastoma is a benign neoplasm, it is locally aggressive
and local recurrence is not rare (Inoue et al. 1988). Ame-
loblastic carcinoma is a term given to tumors that display
histologically malignant features at both primary and* Correspondence: kitajima@med.kobe-u.ac.jp
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provided the original work is properly creditedmetastatic sites with a pattern otherwise resembling ame-
loblastoma (Newman et al. 1995). To plan the most ap-
propriate treatment, it is very important to determine
whether a tumor is benign or malignant. However, dis-
crimination between ameloblastoma and ameloblastic car-
cinoma is difficult by conventional morphological imaging
modalities such as radiography, computed tomography
(CT) and magnetic resonance imaging (MRI) (Devenney-
Cakir et al. 2010, Dunfee et al. 2006, Matsuzaki et al.
2011, Minami et al. 1992).
Recently, assessment of glucose metabolism in cells
using 18F-fluorodeoxyglucose (FDG) positron emission
tomography (PET) has been used to identify aggressive tu-
mors and to predict their degree of malignant potential.
Here we describe a case of ameloblastoma with emphasis
on the imaging features revealed by FDG-PET/CT.le distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Fig. 1 CT imaging findings. a Axial non-contrast CT image shows a 31 × 43 × 46-mm mass in the left maxillary sinus and masticatory space with
resorption and destruction of the maxillary sinus posterior bone. b Coronal CT (bone-window) images show diffuse and partial resorption of the
alveolar bone and elevation of the posterior maxillary sinus floor with destruction of the floor and lateral side wall
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A 78-year-old male patient presented at the otolaryngol-
ogy-head and neck surgery department of our hospital
complaining of nasal bleeding. He had no pain, swelling
or discharge. The patient gave consent to publish this case
report and any accompanying images.
Non-contrast CT revealed a 31 × 43 × 46-mm mass in
the left maxillary sinus and masticatory space, with pos-
terior bone resorption and destruction of the maxillary
sinus (Fig. 1a). The solid mass also showed partial re-
sorption of the alveolar bone and elevation of the poster-
ior maxillary sinus floor with destruction of the floor
and lateral side wall (Fig. 1b). MRI was performed using
a 1.5-T unit. MRI demonstrated hypo- to isointensity
with a heterogeneous pattern on T1-weighted spin-echo
images (repetition time/echo time (TR/TE) = 727/12
ms), heterogeneous hyperintensity with a prominent
high-signal spot on T2-weighted fast spin-echo images
(TR/TE = 4452/100 ms) (Fig. 2a), and high signal intensity
on diffusion-weighted imaging (DWI) (b value = 0 and
1000 s/mm2), reflecting restricted diffusion. T1-weightedFig. 2 MRI findings. a Axial T2-weighted MR image shows heterogeneous
the left maxillary sinus and masticatory space. b Axial contrast-enhanced T1
of the massspin-echo images (TR/TE = 554/10 ms) enhanced with
gadolinium-diethylene-triamine-pentaacetic acid (Gd-
DTPA) (Magnevist: Bayer Schering Pharma, Osaka, Japan)
showed strong and heterogeneous enhancement of the
tumor (Fig. 2b). These findings of marginal bone destruc-
tion by the lesion on CT and MRI and abnormal signal in-
tensity on DWI suggested a malignant tumor, and we first
suspected ameloblastic carcinoma. The differential diag-
nosis included malignant peripheral nerve sheath tumor,
rhabdomyosarcoma, pleomorphic adenocarcinoma or ad-
enoid cystic carcinoma arising from the masticatory space.
For initial staging, FDG-PET/CT was performed to inves-
tigate the presence of regional lymph nodes and distant
metastasis. The mass showed mild FDG uptake with a
maximum standardized uptake value (SUVmax) of 2.40
(Figs. 3a,b). On this basis, we considered the lesion to be a
benign odontogenic tumor, probably ameloblastoma.
We performed biopsy under general anesthesia and
pathological examination of the sample confirmed amelo-
blastoma. Later the patient underwent partial mandibulect-
omy. Gross pathological review revealed a shiny white solidhyperintensity with a prominent high-signal spot of the solid mass in
-weighted MR image shows strong and heterogeneous enhancement
Fig. 3 Findings of 18F-FDG PET/CT imaging. a PET and b fused PET/CT imaging show that the mass has mild FDG uptake with a maximum
standardized uptake value (SUVmax) of 2.40
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dense proliferation of follicular structures made up of
tumor cells resembling odontogenic epithelium. Tall col-
umnar cells resembling ameloblastoma cells formed arrays
surrounding peripheral follicles, which contained a stellate
reticulum-like component in the central area (Fig. 4b). The
pathological diagnosis was ameloblastoma.
At 2 years after surgery, there was no sign of tumor
recurrence.
Discussion
Ameloblastoma is a benign, locally aggressive and infiltra-
tive odontogenic neoplasm with a high rate of recurrence.
Ameloblastic carcinoma tends to be aggressive and has a
potential for lymph node and distant metastasis. Therefore
diagnostic imaging for initial staging before treatment is
very important. Resection of mandibular masses is an ex-
tensive and potentially disfiguring type of surgery; there-
fore preoperative understanding of the extent and
malignant potential of a tumor in this area is essential for
achieving a curative and cosmetically acceptable result.Fig. 4 Histopathological findings. a Gross pathological view demonstrates
eosin staining reveals dense proliferation of follicular structures made up o
resembling ameloblastoma cells surround peripheral follicles, which containHowever, the two neoplasms are morphologically similar
(Devenney-Cakir et al. 2010, Dunfee et al. 2006, Matsuzaki
et al. 2011, Minami et al. 1992), and therefore an add-
itional imaging modality to achieve adequate discrimin-
ation is desirable.
Ameloblastoma and ameloblastic carcinoma most com-
monly occur in the posterior mandible, typically in the re-
gion of the third molar, with associated follicular cysts or
impacted teeth. The slow growth of the tumor can lead to
significant expansion of the mandible. Radiographically,
both lesions can appear radiolucent, being either unilocu-
lar or multilocular, exhibiting a honeycomb-like appear-
ance with tooth root resorption. Both lesions often have
distinct borders, slight marginal sclerosis without perios-
teal new bone formation, loss of the lamina dura, resorp-
tion of the tooth apex and tooth displacement (Devenney-
Cakir et al. 2010, Dunfee et al. 2006). CT findings include
cystic areas of low attenuation with scattered isoattenuat-
ing regions, representating soft tissue components. The le-
sion can also erode through the cortex with extension into
the surrounding oral mucosa (Dunfee et al. 2006). Ina shiny white solid mass. b Microscopic view with hematoxylin and
f tumor cells resembling odontogenic epithelium. Tall columnar cells
stellate reticulum-like central areas
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to ameloblastoma and indicates the aggressive behavior of
the tumor. MRI demonstrates several common findings:
multilocularity, mixed solid and cystic components, ir-
regularly thick walls, papillary projections, and marked en-
hancement of the walls and septa (Dunfee et al. 2006,
Minami et al. 1992). MRI is superior to conventional radi-
ography and CT in demonstrating components of the
tumor, extension within the bone marrow and involve-
ment of adjacent extraosseous structures, which is import-
ant when considering surgical resection or reconstruction
planning (Devenney-Cakir et al. 2010, Dunfee et al. 2006,
Matsuzaki et al. 2011, Minami et al. 1992). Ameloblastic
carcinoma generally exhibits more aggressive features
such as dystrophic calcifications, cortical destruction,
extraosseous extension and an extensive solid component.
Few reports have described the FDG-PET/CT features
of ameloblastoma and ameloblastic carcinoma (Devenney-
Cakir et al. 2010, Matsuzaki et al. 2011, Nguyen 2005,
Otsuru et al 2008). Matsuzaki et al. reported one case of
ameloblastic carcinoma of the maxilla demonstrating in-
tense FDG uptake with a SUVmax of 28.3 (Matsuzaki
et al. 2011). Otsuru et al. reported four cases of amelobl-
stoma (three arising from the maxilla and one from the
mandible) showing mild to moderate FDG uptake, which
was correlated with glucose transporter-1 (GLUT-1) ex-
pression (Otsuru et al 2008). Two groups have demon-
strated that FDG-PET/CT was also useful for detection of
metastases from ameloblastic carcinoma (Devenney-Cakir
et al. 2010, Nguyen 2005). From these previous reports
and the present case, it appears that ameloblastic carcin-
oma shows intense FDG uptake, whereas ameloblastoma
shows mild or moderate FDG uptake, and rarely intense
FDG uptake, however further analysis in a larger patient
population is necessary to confirm this speculation. Low
uptake in this case may be due to weak aggressiveness and
invasiveness of this tumor. Our experience suggests that
FDG-PET/CT may be effective for discriminating amelo-
blastoma from ameloblastic carcinoma. Especially, in cases
showing mild FDG uptake, benign ameloblastoma would
seem the most likely diagnosis. Moreover, as FDG-PET is
useful for predicting the degree of malignant potential and
for identifying ameloblastoma as a locally invasive tumor,
prediction and early diagnosis of recurrent ameloblas-
toma, and personalized treatment in individual cases, may
be possible (Otsuru et al 2008).
Conclusions
We have reported the CT, MRI and FDG-PET/CT find-
ings in a case of maxillar amelobastoma in a 78-year-old
male patient. In this case, it was difficult to distinguish
between amelobastoma and ameloblastic carcinoma by
conventional CT and MRI. Mild FDG uptake on PET/
CT was useful for diagnosis of amelobastoma. FDG-PET/CT may be useful as an adjunctive modality for
diagnosis, treatment planning and surveillance of amelo-
blastoma and ameloblastic carcinoma.
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